The results showed that higher RNF8 expression was associated with a worse overall survival (OS, P = 0.035), worse Relapse Free Survival (RFS, P = 0.013), and worse Distant Metastasis Free survival (DMFS, P = 0.00056) of breast cancer patients, while there was no significant difference in Post Progression Survival (PPS) of breast cancer patients (P = 0.16) (Fig. 8), when the influence of systemic treatment, endocrine therapy, and chemotherapy was excluded. Here, RNF8 is linked to breast cancer.